Anuh Pharma's profit slipped 13% even as revenue rose 17% in FY26
The ₹771 cr pharma company saw a margin squeeze; board recommends ₹1.50 dividend.
— 3 earlier stories on Anuh Pharma Ltd. →What's new
- Revenue grew 16.6% to ₹771.66 crore for FY26.
- Net profit fell 13.3% to ₹41.05 crore, a margin squeeze.
- Board recommended a dividend of ₹1.50 per share.
Why this matters
Anuh Pharma's top line continues to expand, but the bottom line tells a different story. The 13% profit decline amid 17% revenue growth points to margin compression — likely from input costs or competitive pricing. The dividend recommendation signals the board's confidence, but the earnings quality warrants closer scrutiny.
What we're watching
- Whether margin recovery is in sight for the current year.
- Any management commentary on the revenue-profit divergence.
- Impact of promoter reclassification on governance.
The full read
Anuh Pharma's FY26 results show a classic divergence: revenue up, profit down. The company reported sales of ₹771.66 crore, a 16.6% gain, but net profit slipped 13.3% to ₹41.05 crore. The board recommended a ₹1.50 dividend, a routine gesture. The rest of the board meeting covered standard housekeeping: reappointments, auditor appointments, and a previously flagged promoter reclassification. The results are audited and periodic, but the gap between revenue and profit growth is the one fresh data point investors have to work with. It raises questions about cost management or pricing power in the pharma business. Without a concall transcript accompanying this filing, the next test will be whether management addresses the margin compression in subsequent disclosures.
Story so far
All notes on ANUHPHR →- Today · 10:52 PM IST Anuh Pharma's profit slipped 13% even as revenue rose 17% in FY26
- 3d ago Anuh Pharma's FY26 revenue rose 16.6% but profit fell 13.3%
- 4d ago Anuh Pharma revenue up 16%, but profit slips 13% in FY26
- 4d ago Anuh Pharma's profit slipped 13% despite 16.6% revenue growth